---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-328180"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:12:53.971981+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO reports positive interim Phase II data for RGX-314; 71.8% reduction in anti-VEGF injections at 6 months

## Summary
- RGX-314 well tolerated across 50 patients in Cohorts 1-3; no drug-related SAEs.
- Cohort 2 (wet AMD) at 6 months: mean BCVA stable (-0.1 letters from Day1); 71.8% reduction in anti-VEGF burden; 40% injection-free.
- Cohort 1 (diabetic retinopathy) at 3 months: stable BCVA +2.6 letters vs +0.4 control.
- Company plans additional updates; enrollment ongoing in higher-dose cohorts 4/5.

## SEC filing metadata
- accession: 0001193125-21-328180
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312521328180/0001193125-21-328180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312521328180/d142076d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-328180
- JSON: https://secwatch.observer/filing/0001193125-21-328180.json
- Plain text: https://secwatch.observer/filing/0001193125-21-328180.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.